Publications & Presentations

Publications & Presentations

Search Result :- Notice: Undefined index: y in /www/wp-content/themes/glenmark_us/parts/content-publicationscopy.php on line 135

Is an investigational new drug that has not been approved for commercial distribution in the United States.

May 30, 2019
Rapid Nasal Symptom Onset Of Action And Ocular Symptom Relief With Olopatadine/Mometasone Combination Nasal Spray In Patients With Seasonal Allergic Rhinitis: A Pooled Analysis
May 30, 2019
Olopatadine/Mometasone Combination Nasal Spray for the Treatment of Seasonal Allergic Rhinitis: A Pooled Analysis of Efficacy and Safety
March 1, 2019
Evidence For Activity Of GBR 830 (Anti-OX40) In Extrinsic And Intrinsic Atopic Dermatitis (AD) In A Phase 2A Study
February 22, 2019
Olopatadine/Mometasone Combination Nasal Spray For The Treatment Of Seasonal Allergic Rhinitis: A Pooled Analysis Of Efficacy And Safety
February 22, 2019
Quality Of Life Improvements Following Treatment With Olopatadine/Mometasone Combination Nasal Spray For The Treatment Of Seasonal Allergic Rhinitis: A Pooled Analysis
February 22, 2019
Rapid Nasal Symptom Onset Of Action And Ocular Symptom Relief With Olopatadine/Mometasone Combination Nasal Spray In Patients With Seasonal Allergic Rhinitis: A Pooled Analysis
February 22, 2019
Evidence For Activity Of GBR 830 (Anti-OX40) In Extrinsic And Intrinsic Atopic Dermatitis (AD) In A Phase 2A Study
February 6, 2019
GBR 830, An Anti-OX40, Improves Skin Gene Signatures And Clinical Scores In Patients  With Atopic Dermatitis
January 26, 2019
Clinical Pharmokinetics And Immunogenicity Of GBR 830, A First-In-Class Humanized Monoclonal Antibody Inhibiting OX40 To Treat Atopic Dermatitis
January 26, 2019
GBR 830 Induces Progressive And Sustained Improvements In Atopic Dermatitis Skin Biomarkers And Clinical Parameters
January 20, 2019
Morning And Evening Nasal Symptom Improvement With Olopatadine/Mometasone Combination Nasal Spray In Patients With Seasonal Allergic Rhinitis
December 13, 2018
Preliminary Pharmacokinetic Results From a Phase 1 Study of GBR 1302 in Patients With HER2-Positive Cancers
November 15, 2018
Long-Term Safety And Efficacy Of Olopatadine/Mometasone Combination Nasal Spray In Patients With Perennial Allergic Rhinitis
November 15, 2018
Seasonal Allergic Rhinitis Nasal Symptoms And Quality Of Life With Olopatadine/Mometasone Combination Nasal Spray
November 15, 2018
Olopatadine/Mometasone Combination Nasal Spray Effectively Improves Seasonal Allergic Rhinitis Nasal Symptoms And Quality Of Life
July 22, 2018
Efficacy And Safety Of Olopatadine/Mometasone Combination Nasal Spray For The Treatment Of Seasonal Allergic Rhinitis
July 22, 2018
Rapid Onset Of Action And Improvement Of Nasal And Ocular Symptoms With Olopatadine/Mometasone Combination Nasal Spray In Patients With Seasonal Allergic Rhinitis
June 26, 2018
Olopatadine/Mometasone Combination Nasal Spray Improves Nasal Symptoms In Seasonal Allergic Rhinitis Patients
June 26, 2018
Olopatadine/Mometasone Combination Nasal Spray Provides Rapid Onset Of Action And Improves Ocular Symptoms In Patients With Seasonal Allergic Rhinitis
June 1, 2018
Phase 1, Multicenter, Open-Label Study Of Single-Agent Bispecific Antibody T Cell Engager GBR 1342 In Relapsed/Refractory Multiple Myeloma
June 1, 2018
GBR 1302: Effect Of CD3-HER2, A Bispecific T Cell Engager Antibody, In Trastuzumab-Resistant Cancers
May 31, 2018
Efficacy And Safety Of Olopatadine/Mometasone Combination Nasal Spray For The Treatment Of Seasonal Allergic Rhinitis
May 31, 2018
Rapid Onset Of Action And Improvement Of Nasal And Ocular Symptoms With Olopatadine/Mometasone Combination Nasal Spray In Patients With Seasonal Allergic Rhinitis
May 16, 2018
GBR 830: An OX40 Antagonist Antibody With A Favorable Toxicity Profile In Non-Human Primates
May 16, 2018
Clinical Pharmacokinetics And Immunogenicity Of GBR 830, A First-In-Class Humanized Monoclonal Antibody Inhibiting OX40 To Treat Atopic Dermatitis
May 16, 2018
Targeting OX40 With GBR 830, An OX40 Antagonist, Inhibits T Cell-Mediated Pathological Responses
May 16, 2018
GBR 830 Induces Progressive And Sustained Improvements In Atopic Dermatitis Skin Biomarkers And Clinical Parameters
May 1, 2018
Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations
May 1, 2018
Pharmacokinetics of intranasal olopatadine in the fixed-dose combination GSP301 versus two monotherapy intranasal olopatadine formulations
April 11, 2018
Results From A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Exploratory, Multicenter Study Of GBR 830 In Adult Patients With Moderate-To-Severe Atopic Dermatitis
March 2, 2018
Rapid Onset Of Action On Nasal Symptoms And Ocular Symptom Relief With Olopatadine/Mometasone Combination Nasal Spray In A Ragweed Environmental Exposure Chamber
March 2, 2018
Rapid Onset Of Action On Nasal Symptoms And Ocular Symptom Improvement With Olopatadine/Mometasone Combination Nasal Spray In Patients With Seasonal Allergic Rhinitis
March 2, 2018
Efficacy And Safety Of Olopatadine/Mometasone Combination Nasal Spray In Patients With Seasonal Allergic Rhinitis
February 16, 2018
Results From A Randomized, Double-Blind, Placebo‐Controlled, Exploratory, Multicenter Study Of GBR 830 In Adult Patients With Moderate-To-Severe Atopic Dermatitis
January 25, 2018
Preliminary Biomarker And Pharmacodynamic Data From A Phase 1 Study Of Single-Agent Bispecific Antibody T Cell Engager GBR 1302 In Subjects With HER2‐Positive Cancers
January 25, 2018
Phase 1, Multicenter, Open-Label Study Of Single-Agent Bispecific Antibody T Cell Engager GBR 1342 In Relapsed/Refractory Multiple Myeloma
October 26, 2017
Efficacy And Safety Of Olopatadine/Mometasone Combination Nasal Spray For The Treatment Of Seasonal Allergic Rhinitis
October 26, 2017
Olopatadine/Mometasone Combination Nasal Spray Improves Seasonal Allergic Rhinitis Symptoms In A 
Ragweed Environmental Exposure Chamber
October 26, 2017
Efficacy And Safety Of Once-Daily And Twice-Daily Olopatadine/Mometasone Nasal Spray Treatment In Seasonal Allergic Rhinitis
November 10, 2016
Pharmacokinetics Of Mometasone Furoate Administered As GSP301 Nasal Spray Versus Mometasone Monotherapy
November 10, 2016
Pharmacokinetics Of Olopatadine Administered As GSP301 Nasal Spray Versus Olopatadine Monotherapy
November 4, 2016
A Phase 1 Study Of GBR 1302 In Subjects With HER2-Positive Cancers
November 4, 2016
A Phase 1 Study Of The Bispecific Antibody T Cell Engager GBR 1302 In Subjects With HER2-Positive Cancers
Notice: Undefined index: the_cookie in /www/wp-content/themes/glenmark_us/parts/content-publicationscopy.php on line 178

ONCOLOGY

IMMUNOLOGY

RESPIRATORY

*An investigational new drug that has not been approved for commercial distribution in the United States

Publications & Presentations

ONCOLOGY

GBR 1302

Is an investigational new drug that has not been approved for commercial distribution in the United States.

Notice: Undefined variable: tags in /www/wp-content/themes/glenmark_us/parts/content-publicationscopy.php on line 254
December 13, 2018
Preliminary Pharmacokinetic Results From a Phase 1 Study of GBR 1302 in Patients With HER2-Positive Cancers
June 1, 2018
GBR 1302: Effect Of CD3-HER2, A Bispecific T Cell Engager Antibody, In Trastuzumab-Resistant Cancers
January 25, 2018
Preliminary Biomarker And Pharmacodynamic Data From A Phase 1 Study Of Single-Agent Bispecific Antibody T Cell Engager GBR 1302 In Subjects With HER2‐Positive Cancers
November 4, 2016
A Phase 1 Study Of GBR 1302 In Subjects With HER2-Positive Cancers
November 4, 2016
A Phase 1 Study Of The Bispecific Antibody T Cell Engager GBR 1302 In Subjects With HER2-Positive Cancers

Publications & Presentations

ONCOLOGY

GBR 1342

Is an investigational new drug that has not been approved for commercial distribution in the United States.

Notice: Undefined variable: tags in /www/wp-content/themes/glenmark_us/parts/content-publicationscopy.php on line 294

Publications & Presentations

IMMUNOLOGY

GBR 830

Is an investigational new drug that has not been approved for commercial distribution in the United States.

Notice: Undefined variable: tags in /www/wp-content/themes/glenmark_us/parts/content-publicationscopy.php on line 331

Publications & Presentations

RESPIRATORY

RyaltrisTM (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg])

Is an investigational new drug that has not been approved for commercial distribution in the United States.

Notice: Undefined variable: tags in /www/wp-content/themes/glenmark_us/parts/content-publicationscopy.php on line 368